Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -726.4 Million USD | -3.61% |
| 2022 | -166 Million USD | -147.08% |
| 2021 | 352.6 Million USD | -18.72% |
| 2020 | 433.8 Million USD | 280.19% |
| 2019 | 114.1 Million USD | 27.06% |
| 2018 | 89.8 Million USD | -27.75% |
| 2017 | 124.28 Million USD | 17.78% |
| 2016 | 105.52 Million USD | 9.87% |
| 2015 | 96.03 Million USD | 65.42% |
| 2014 | 58.05 Million USD | 35.64% |
| 2013 | 42.8 Million USD | 42.83% |
| 2012 | 29.96 Million USD | -6.64% |
| 2011 | 32.09 Million USD | -56.36% |
| 2010 | 73.55 Million USD | 83.21% |
| 2009 | 40.15 Million USD | 34.16% |
| 2008 | 29.92 Million USD | -9.57% |
| 2007 | 33.09 Million USD | -12.98% |
| 2006 | 38.02 Million USD | 78.23% |
| 2005 | 21.33 Million USD | 27.22% |
| 2004 | 16.77 Million USD | -69.93% |
| 2003 | 55.76 Million USD | 47.67% |
| 2002 | 37.76 Million USD | 10475.55% |
| 2001 | -364 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -159.1 Million USD | -499.75% |
| 2024 Q1 | 39.8 Million USD | 194.99% |
| 2023 Q4 | -41.9 Million USD | 82.69% |
| 2023 Q1 | -148.1 Million USD | -153.6% |
| 2023 Q2 | -292.9 Million USD | -97.77% |
| 2023 FY | -172 Million USD | -3.61% |
| 2023 Q3 | -242.1 Million USD | 17.34% |
| 2022 Q4 | -58.4 Million USD | -39.05% |
| 2022 Q2 | -72 Million USD | -1225.0% |
| 2022 Q3 | -42 Million USD | 41.67% |
| 2022 Q1 | 6.4 Million USD | -97.69% |
| 2022 FY | -166 Million USD | -147.08% |
| 2021 Q4 | 277.4 Million USD | 899.42% |
| 2021 FY | 352.6 Million USD | -18.72% |
| 2021 Q1 | 95.4 Million USD | -63.04% |
| 2021 Q2 | 14.5 Million USD | -84.8% |
| 2021 Q3 | -34.7 Million USD | -339.31% |
| 2020 Q3 | 61.3 Million USD | -51.35% |
| 2020 Q2 | 126 Million USD | 1186.21% |
| 2020 Q1 | -11.6 Million USD | -114.91% |
| 2020 FY | 433.8 Million USD | 280.19% |
| 2020 Q4 | 258.1 Million USD | 321.04% |
| 2019 Q3 | 70.7 Million USD | 1110.0% |
| 2019 FY | 114.1 Million USD | 27.06% |
| 2019 Q1 | -27.2 Million USD | -342.86% |
| 2019 Q2 | -7 Million USD | 74.26% |
| 2019 Q4 | 77.8 Million USD | 10.04% |
| 2018 Q2 | 66.77 Million USD | 804.02% |
| 2018 Q4 | 11.2 Million USD | -47.44% |
| 2018 FY | 89.8 Million USD | -27.75% |
| 2018 Q1 | -9.48 Million USD | -117.87% |
| 2018 Q3 | 21.31 Million USD | -68.09% |
| 2017 Q3 | 47.76 Million USD | 460.08% |
| 2017 FY | 124.28 Million USD | 17.78% |
| 2017 Q1 | 14.91 Million USD | -70.72% |
| 2017 Q2 | 8.52 Million USD | -42.8% |
| 2017 Q4 | 53.07 Million USD | 11.11% |
| 2016 FY | 105.52 Million USD | 9.87% |
| 2016 Q2 | -13.62 Million USD | -259.09% |
| 2016 Q4 | 50.92 Million USD | 43.55% |
| 2016 Q3 | 35.47 Million USD | 360.48% |
| 2016 Q1 | 8.56 Million USD | -82.84% |
| 2015 Q4 | 49.89 Million USD | -5.87% |
| 2015 Q1 | -28.31 Million USD | -163.45% |
| 2015 FY | 96.03 Million USD | 65.42% |
| 2015 Q2 | 21.45 Million USD | 175.78% |
| 2015 Q3 | 53 Million USD | 147.09% |
| 2014 Q4 | 44.62 Million USD | 43.79% |
| 2014 FY | 58.05 Million USD | 35.64% |
| 2014 Q2 | 7.86 Million USD | 130.88% |
| 2014 Q1 | -25.45 Million USD | -209.29% |
| 2014 Q3 | 31.03 Million USD | 294.71% |
| 2013 Q2 | 14.71 Million USD | 210.2% |
| 2013 Q3 | 18.14 Million USD | 23.35% |
| 2013 FY | 42.8 Million USD | 42.83% |
| 2013 Q4 | 23.29 Million USD | 28.36% |
| 2013 Q1 | -13.35 Million USD | -155.54% |
| 2012 Q1 | -12.53 Million USD | -127.26% |
| 2012 Q2 | 8.65 Million USD | 169.01% |
| 2012 Q3 | 9.81 Million USD | 13.45% |
| 2012 FY | 29.96 Million USD | -6.64% |
| 2012 Q4 | 24.03 Million USD | 144.83% |
| 2011 Q1 | -35.5 Million USD | -201.55% |
| 2011 Q3 | 1.4 Million USD | -93.03% |
| 2011 Q2 | 20.2 Million USD | 156.91% |
| 2011 FY | 32.09 Million USD | -56.36% |
| 2011 Q4 | 45.99 Million USD | 3166.34% |
| 2010 Q1 | 3.17 Million USD | -22.96% |
| 2010 Q4 | 34.96 Million USD | 69.68% |
| 2010 FY | 73.55 Million USD | 83.21% |
| 2010 Q3 | 20.6 Million USD | 39.12% |
| 2010 Q2 | 14.81 Million USD | 366.05% |
| 2009 Q3 | -3.95 Million USD | -117.4% |
| 2009 Q2 | 22.71 Million USD | 31.53% |
| 2009 FY | 40.15 Million USD | 34.16% |
| 2009 Q1 | 17.26 Million USD | 1921.78% |
| 2009 Q4 | 4.12 Million USD | 204.4% |
| 2008 Q4 | 854 Thousand USD | -94.43% |
| 2008 Q1 | 11.17 Million USD | -74.11% |
| 2008 Q2 | 2.55 Million USD | -77.11% |
| 2008 FY | 29.92 Million USD | -9.57% |
| 2008 Q3 | 15.33 Million USD | 499.61% |
| 2007 Q1 | -5.83 Million USD | -113.28% |
| 2007 Q4 | 43.15 Million USD | 875.98% |
| 2007 Q3 | 4.42 Million USD | 151.08% |
| 2007 Q2 | -8.65 Million USD | -48.47% |
| 2007 FY | 33.09 Million USD | -12.98% |
| 2006 Q1 | 21.94 Million USD | 156.29% |
| 2006 FY | 38.02 Million USD | 78.23% |
| 2006 Q4 | 43.89 Million USD | 2343.18% |
| 2006 Q3 | -1.95 Million USD | -108.92% |
| 2006 Q2 | 21.94 Million USD | 0.0% |
| 2005 Q2 | 28.96 Million USD | 0.0% |
| 2005 Q3 | 28.96 Million USD | 0.0% |
| 2005 FY | 21.33 Million USD | 27.22% |
| 2005 Q1 | 28.96 Million USD | 158.32% |
| 2005 Q4 | -38.98 Million USD | -234.6% |
| 2004 Q3 | 20.87 Million USD | 0.0% |
| 2004 Q2 | 20.87 Million USD | 0.0% |
| 2004 Q4 | -49.66 Million USD | -337.95% |
| 2004 FY | 16.77 Million USD | -69.93% |
| 2004 Q1 | 20.87 Million USD | 0.0% |
| 2003 FY | 55.76 Million USD | 47.67% |
| 2002 FY | 37.76 Million USD | 10475.55% |
| 2001 FY | -364 Thousand USD | 0.0% |
| 2001 Q4 | -65.1 Million USD | -87.61% |
| 2001 Q3 | -34.7 Million USD | 88.15% |
| 2001 Q2 | -292.9 Million USD | -4676.56% |
| 2001 Q1 | 6.4 Million USD | 109.83% |
| 2000 Q4 | -65.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 204.37 Million USD | 455.427% |
| Bausch Health Companies Inc. | 963 Million USD | 175.431% |
| Catalent, Inc. | -749 Million USD | 3.017% |
| Elanco Animal Health Incorporated | 326 Million USD | 322.822% |
| Perrigo Company plc | 151.9 Million USD | 578.209% |
| Teva Pharmaceutical Industries Limited | 433 Million USD | 267.76% |
| Zoetis Inc. | 3.06 Billion USD | 123.669% |